MedTrace Logo

Efficacy of Multimodal Analgesia Following Hip Arthroscopy

NCT03351439 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-10-15

No results posted yet for this study

Summary

The purpose of the full study is to determine whether multimodal analgesia for hip arthroscopy will reduce post-operative pain scores, narcotic consumption and hospital length-of-stay. To do this, the investigators will compare the standard of care (SOC), with routine pain management with a post-operative opioid prescription, to three different groups with multi-modal analgesia (SOC+peri-operative celecoxib, SOC+peri-operative gabapentin, and SOC+post-operative zopiclone).

The investigators hypothesize that administration of multi-modal analgesia in all three treatment groups will result in improved post-operative pain control, reduced post-operative narcotic consumption and an overall reduction in post-operative length-of-stay compared to the group receiving treatment as per the standard of care. However, prior to undertaking a large multi-centre study, the investigators need to determine whether the study is feasible from data obtained with this pilot study.

Conditions

  • Hip Pain Chronic

Interventions

DRUG

Zopiclone

Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days

DRUG

Gabapentin

Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively

DRUG

Celebrex

Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively

DRUG

Percocet

Standard of Care

DRUG

Naprosyn

Standard of Care

Sponsors & Collaborators

  • Western University, Canada

    lead OTHER

Principal Investigators

  • Ryan Degen, MD, FRCSC · Fowler Kennedy Sport Medicine Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-06
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03351439 on ClinicalTrials.gov